Drugs / HDM1005
last change Jul 2026 re-read 2 minutes ago

HDM1005

Developed for
obesity disorder · type 2 diabetes mellitus · morbid obesity
Investigated by
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT07559240 May → Jun 2026 overdue obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT07502001 Apr → Dec 2026 expected obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT06637020 Jun → Dec 2024 morbid obesity Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 1 NCT06640647 Mar → Aug 2024 obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT07521631 Mar 2026 → Feb 2027 expected obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT07109700 Apr 2025 → Jan 2026 overdue type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT06886126 Feb → Sep 2025 overdue obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 33 trials
Phase 3 NCT07417306 Mar 2026 → Aug 2027 expected type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07394114 Feb 2026 → Aug 2027 expected type 2 diabetes mellitus Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT07279194 Oct 2025 → Sep 2026 expected obesity disorder Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as HDM1005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07521631
9

NCT07279194

NCT07394114

NCT07417306

NCT06640647

NCT06886126

NCT07109700

NCT06637020

NCT07559240

NCT07502001

Route Subcutaneous “receive either HDM1005 injection or placebo subcutaneously” NCT06637020